Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.41 |
| ▸ | TPH1 | P17752 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | MTTP | P55157 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297366 | 0.85 | FAAH (0.50) | FAAH | |
| Trifluoroacetic Acid SCHEMBL4303325 | 0.83 | FAAH (0.57) | FAAHTRPV3TPH1 | |
| SCHEMBL4295329 | 0.81 | FAAH (0.69) | FAAH | |
| SCHEMBL3408600 | 0.81 | FAAH (0.62) | FAAHTRPV3 | |
| SCHEMBL13663433 | 0.81 | FAAH (0.62) | FAAHTRPV3 | |
| SCHEMBL4291955 | 0.74 | FAAH (0.54) | FAAH | |
| SCHEMBL4297032 | 0.73 | FAAH (0.52) | FAAH | |
| SCHEMBL4290239 | 0.72 | FAAH (0.55) | FAAH | |
| SCHEMBL4294829 | 0.72 | FAAH (0.65) | FAAH | |
| SCHEMBL4297639 | 0.71 | FAAH (0.48) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598202-B2 | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-03 | — | — | US | disclosed |
| EP-2254415-B1 | ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-20090264429-A1 | Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264429-A1 | Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase | FAAH, FAAH2, HRH2 | FAAH 1/4885TRPV3 2900/4885TPH1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.